Historic USD 15.2 Billion Pharma Collaboration Between Jiangsu Hengrui and Bristol Myers Squibb

China's Jiangsu Hengrui Pharmaceutical signed a USD 15.2 billion deal with Bristol Myers Squibb, showcasing China's rise in pharmaceutical innovation. The agreement covers oncology, haematology, and immunology programs and highlights China's growing role in global drug development.

In a significant move reinforcing China's emerging role in pharmaceutical innovation, Jiangsu Hengrui Pharmaceutical has entered into a USD 15.2 billion collaboration agreement with American giant Bristol Myers Squibb.

The deal, announced ahead of US President Trump's visit to Beijing, covers 13 preclinical programs in oncology, haematology, and immunology, showcasing China's evolution from a low-cost manufacturing hub to a leader in novel drug discovery.

The agreement underscores the potential of the Chinese pharmaceutical industry on the global stage, as it progresses from its historical role in active pharmaceutical ingredients and generics to pioneering new drugs and therapies.